Elixxer Financial Statements From 2010 to 2025
| ELIXF Stock | USD 0.01 0.02 68.45% |
Check Elixxer financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Elixxer's main balance sheet or income statement drivers, such as , as well as many indicators such as . Elixxer financial statements analysis is a perfect complement when working with Elixxer Valuation or Volatility modules.
Elixxer |
Elixxer Company Current Valuation Analysis
Elixxer's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Elixxer Current Valuation | 9.36 M |
Most of Elixxer's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Elixxer is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Elixxer has a Current Valuation of 9.36 M. This is 99.93% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The current valuation for all United States stocks is 99.94% higher than that of the company.
Elixxer Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Elixxer's current stock value. Our valuation model uses many indicators to compare Elixxer value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Elixxer competition to find correlations between indicators driving Elixxer's intrinsic value. More Info.Elixxer is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Elixxer's earnings, one of the primary drivers of an investment's value.About Elixxer Financial Statements
Elixxer stakeholders use historical fundamental indicators, such as Elixxer's revenue or net income, to determine how well the company is positioned to perform in the future. Although Elixxer investors may analyze each financial statement separately, they are all interrelated. For example, changes in Elixxer's assets and liabilities are reflected in the revenues and expenses on Elixxer's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Elixxer. Please read more on our technical analysis and fundamental analysis pages.
Elixxer Ltd. operates as a cannabis investment firm in Canada, Australia, Italy, Jamaica, and Switzerland. Elixxer Ltd. was incorporated in 2004 and is based in Montreal, Canada. Elixxer is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Elixxer Pink Sheet
Elixxer financial ratios help investors to determine whether Elixxer Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Elixxer with respect to the benefits of owning Elixxer security.